

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Antengene Corporation Limited

德琪醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6996)

VOLUNTARY ANNOUNCEMENT

ACKNOWLEDGEMENT OF CTN BY THE TGA FOR PHASE I CLINICAL TRIAL OF ATG-101 IN SOLID TUMORS AND NON-HODGKIN LYMPHOMAS

This announcement is made by Antengene Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group. The board of directors of the Company (the “**Board**”) is pleased to announce that the filing of the first clinical trial of ATG-101 in patients with metastatic/advanced solid tumors and B-cell non-Hodgkin lymphomas (B-NHL) has been approved by the Bellberry Human Research Ethics Committee (“**HREC**”) in Sydney, and Clinical Trial Notification (“**CTN**”) has been acknowledged by the Therapeutic Goods Administration (“**TGA**”), Australia on August 31, 2021. The Phase I clinical trial of ATG-101 is now permitted to commence in Australia and will be initiated in the near future.

This is a voluntary announcement made by the Company. The Group cannot guarantee that ATG-101 will ultimately be successfully developed and marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

About ATG-101

ATG-101 is a novel PD-L1/4-1BB bi-specific antibody being developed for the treatment of cancer. ATG-101 can activate anti-tumor immune effectors by simultaneously blocking PD-L1/PD-1 binding and inducing 4-1BB stimulation. In the presence of PD-L1 over-expressed cancer cells, ATG-101 has shown significant PD-L1 crosslinking-dependent 4-1BB agonist activity, thus potentially enhancing therapeutic efficacy, whilst mitigating risk of hepatotoxicity.

About Antengene

Antengene Corporation Limited (“**Antengene**”, SEHK: 6996.HK) is a leading clinical-stage R&D – driven biopharmaceutical company focused on innovative medicines for oncology and other life-threatening diseases. Antengene aims to provide the most advanced anti-cancer drugs to patients in the Asia Pacific Region and around the world. Since its establishment in 2017, Antengene has obtained 16 investigational new drug (IND) approvals, submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, and was granted an NDA approval in South Korea through a priority review process. Leveraging partnerships as well as in-house drug discovery, Antengene has built a broad and expanding pipeline of 13 clinical and pre-clinical assets, comprising 8 global rights assets and 5 assets with rights for Asia Pacific markets including the Greater China region. Driven by its vision of “Treating Patients Beyond Borders”, Antengene is committed to addressing significant unmet medical needs by discovering, developing, manufacturing and commercializing first-in-class/best-in-class therapeutics.

Forward-looking statements

The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development.

By order of the Board
Antengene Corporation Limited
Dr. Jay Mei
Chairman

Hong Kong, September 2, 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Jay Mei, Mr. John F. Chin, Dr. Kevin Patrick Lynch and Mr. Donald Andrew Lung as executive directors; Mr. Yanling Cao and Dr. Kan Chen as non-executive directors; and Mr. Mark J. Alles, Ms. Jing Qian and Mr. Sheng Tang as independent non-executive directors.